It was impossible to judge in 7 patients whether, before IC, they had NSCLC LM that was sensitive to subsequent targeted therapy because they had not received a third-generation EGFR-TKI and did not have next-generation sequencing results of cerebrospinal fluid. Here, EGFR is linked to non-small cell lung carcinoma.